Evogene (EVGN) Stock Price, News & Analysis

Company Overview

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.

Key Stats

• Today's Range: $2.49 to $2.87
• 50-Day Range: $2.14 to $4.16
• 52-Week Range: $2.14 to $10.40
• Volume: 65,615 shs
• Average Volume: 19,828 shs
• Market Capitalization: $103.45 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.00
• Consensus Rating: Buy

Evogene Stock Analysis - MarketRank™

Evogene scored higher than 61% of companies evaluated by MarketBeat, and ranked 419th out of 999 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Evogene has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Evogene has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Evogene is -0.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Evogene is -0.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Evogene has a P/B Ratio of 0.36. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.29% of the float of Evogene has been sold short.

Short Interest Ratio / Days to Cover

Evogene has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Evogene has recently decreased by 39.67%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Evogene does not currently pay a dividend.

Dividend Growth

Evogene does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.29% of the float of Evogene has been sold short.

Short Interest Ratio / Days to Cover

Evogene has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Evogene has recently decreased by 39.67%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.30

News Sentiment

Evogene has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Evogene this week, compared to 1 article on an average week.

Search Interest

1 people have searched for EVGN on MarketBeat in the last 30 days.

MarketBeat Follows

3 people have added Evogene to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Evogene insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 7.40% of the stock of Evogene is held by insiders.

Percentage Held by Institutions

Only 10.40% of the stock of Evogene is held by institutions.

EVGN Stock Analysis - Frequently Asked Questions

How have EVGN shares performed this year?

Evogene's stock was trading at $8.40 at the beginning of the year. Since then, EVGN stock has decreased by 70.1% and is now trading at $2.51.
View the best growth stocks for 2024 here.

How were Evogene's earnings last quarter?

Evogene Ltd. (NASDAQ:EVGN) released its quarterly earnings data on Thursday, August, 22nd. The biotechnology company reported ($1.06) earnings per share for the quarter, missing the consensus estimate of ($0.12) by $0.94. The biotechnology company had revenue of $0.91 million for the quarter. Evogene had a negative net margin of 210.26% and a negative trailing twelve-month return on equity of 72.33%.

When did Evogene's stock split?

Evogene's stock reverse split on the morning of Thursday, July 25th 2024. The 1-10 reverse split was announced on Tuesday, July 23rd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 24th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Who are Evogene's major shareholders?

Evogene's top institutional investors include Renaissance Investment Group LLC (0.02%).

How do I buy shares of Evogene?

Shares of EVGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Evogene own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Evogene investors own include Tesla (TSLA), NIO (NIO), Palantir Technologies (PLTR), NVIDIA (NVDA), Plug Power (PLUG), Riot Platforms (RIOT) and AquaBounty Technologies (AQB).

Company Calendar

• Last Earnings: 8/22/2024
• Today: 10/24/2024
• Next Earnings (Estimated): 11/20/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Agricultural chemicals
• Sub-Industry: Chemicals
• Current Symbol: NASDAQ:EVGN
• CUSIP: N/A
• CIK: 1574565
• Web: www.evogene.com
• Phone: (728) 931-1900
• Fax: 972-8946-6724
• Employees: 140
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $12.00
• High Stock Price Target: $12.00
• Low Stock Price Target: $12.00
• Potential Upside/Downside: +378.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.46)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-23,880,000.00
• Net Margins: -210.26%
• Pretax Margin: -222.60%
• Return on Equity: -72.33%
• Return on Assets: -40.42%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.37
• Quick Ratio: 4.24

Sales & Book Value

• Annual Sales: $9.45 million
• Price / Sales: 10.95
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.96 per share
• Price / Book: 0.36

Miscellaneous

• Outstanding Shares: 41,216,000
• Free Float: N/A
• Market Cap: $103.45 million
• Optionable: Optionable
• Beta: 1.40